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Background: Caffeic acid phenethyl ester (CAPE) has been shown to protect the heart against ischemia/reperfusion
(I/R) injury by various mechanisms including its antioxidant effect. In this study, we evaluated the protective effects
of a CAPE analog with more structural stability in plasma, caffeic acid phenethyl amide (CAPA), on I/R injury in
streptozotocin (STZ)-induced type 1 diabetic rats.
Methods: Type 1 diabetes mellitus was induced in Sprague–Dawley rats by a single intravenous injection of
60 mg/kg STZ. To produce the I/R injury, the left anterior descending coronary artery was occluded for 45 minutes,
followed by 2 hours of reperfusion. CAPA was pretreated intraperitoneally 30 minutes before reperfusion. An analog
devoid of the antioxidant property of CAPA, dimethoxyl CAPA (dmCAPA), and a nitric oxide synthase (NOS)
inhibitor (Nω-nitro-L-arginine methyl ester [L-NAME]) were used to evaluate the mechanism involved in the
reduction of the infarct size following CAPA-treatment. Finally, the cardioprotective effect of chronic treatment of
CAPA was analyzed in diabetic rats.
Results: Compared to the control group, CAPA administration (3 and 15 mg/kg) significantly reduced the
myocardial infarct size after I/R, while dmCAPA (15 mg/kg) had no cardioprotective effect. Interestingly,
pretreatment with a NOS inhibitor, (L-NAME, 3 mg/kg) eliminated the effect of CAPA on myocardial infarction.
Additionally, a 4-week CAPA treatment (1 mg/kg, orally, once daily) started 4 weeks after STZ-induction could
effectively decrease the infarct size and ameliorate the cardiac dysfunction by pressure-volume loop analysis in
STZ-induced diabetic animals.
Conclusions: CAPA, which is structurally similar to CAPE, exerts cardioprotective activity in I/R injury through its
antioxidant property and by preserving nitric oxide levels. On the other hand, chronic CAPA treatment could also
ameliorate cardiac dysfunction in diabetic animals.
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Numerous clinical studies have shown that subjects with
diabetes face an increased risk of mortality from coronary
heart disease, such as myocardial infarction and stroke [1].
Accordingly, the infarct size of the heart is increased in
streptozotocin (STZ)-induced type 1 diabetic rats under
ischemia/reperfusion (I/R) injury [2,3].
In the pathology of myocardial infarction, injury is more
dominant from reperfusion than that from ischemia and
reactive oxygen species (ROS) generation is thought to be
the main cause of reperfusion injury [4]. Therefore, anti-
oxidant therapy should effectively reduce I/R injury [5].
Caffeic acid phenethyl ester (CAPE) is the major com-
ponent in propolis extracts with known anti-inflammatory
[6], anti-viral [7], cancer cell inhibitory [8], anti-bacterial
[9], antioxidant [10], and free radical scavenging activities
[9]. CAPE significantly decreased fasting blood glucose,
alanine aminotransferase, cholesterol, and triglyceride levels
and protected the brain against oxidative stress and inflam-
mation in diabetic rats [11,12]. The 12-week oral adminis-
tration of CAPE (30 mg/kg) slowed the atherosclerosis
progress in apolipoprotein E-deficient mice [13]. In addition,
CAPE administration protects many organs such as the
brain [14], bone marrow [14,15], kidney [16], lung [17]
and ovary [18] against I/R injury. In the heart, CAPE can
also protect against I/R injury by various mechanisms
[19-23] including its antioxidant activity.
A CAPE analog, caffeic acid phenethyl amide (CAPA,
N-trans-caffeoyl-β-phenethylamine), synthesized from 3,4-
methylene-dioxy-cinnamic acid, with an amide linkage
between caffeic acid and the phenethyl group that resists
hydrolysis within the circulation, was recently found to be
more stable than CAPE in rat plasma [24]. CAPA presents
a significantly longer elimination half-life in the systemic
circulation than CAPE after intravenous administration
into male rats [25]. It exerts beneficial effects by its free
radical scavenging and antioxidant activity [26,27] andFigure 1 Chemical structures of CAPE, CAPA and dmCAPA.displays a cytoprotective effect against H2O2-induced cell
death in human umbilical vascular endothelial cells [28].
CAPA could also improve glucose homeostasis by α-
glucosidase inhibition [29], adiponectin induction [30]
in vitro, stimulating insulin secretion and reducing plasma
glucose in diabetic rats and mice [31,32]. It has also been
shown to attenuate the progression of vascular dysfunc-
tion in diabetic rats [31], protect hearts against diet- and
STZ- induced metabolic changes and decrease infarct size
after global I/R by increasing coronary flow [33], and
mitigate cardiac dysfunction in abdominal aortic banding-
induced ventricular hypertrophy [34], indicating that CAPA
may be beneficial in the treatment of diabetes and its
cardiovascular complications.
The aim of this study was to characterize the effects of
CAPA on I/R injury in normal and type 1 diabetic rats.
Research design and methods
Chemicals
Sodium pentobarbital, STZ, Nω-nitro-L-arginine methyl
ester (L-NAME), thiobutabarbital sodium salt hydrate
(Inactin® salt hydrate), methylene blue, 2,3,5-triphenyl-
tetrazolium chloride (TTC), and poly-ethylene glycol
400 (PEG400) were purchased from Sigma-Aldrich, MO,
USA. The chemicals for the physiological buffer were pur-
chased from J.T. Baker, Capital Scientific Inc. and Wako
Pure Chemical Industries. CAPA and 3,4-dimethoxyl caffeic
acid phenethyl amide (dmCAPA, Figure 1) were synthe-
sized and obtained from Institute of Chemistry, National
Taiwan University [31]. CAPA was dissolved in PEG400
30% for intraperitoneal injection or suspended in distilled
water for oral administration.
Animals and the induction of diabetic rats
Eight-week-old male Sprague–Dawley rats (BioLASCO
Taiwan, Co., Ltd, Taipei, Taiwan) weighing 250–300 g
(bred in a Lab Animal Center, National Taiwan University,
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tioned environment (22 ± 1°C, 55 ± 5% relative humidity,
12-h light and darkness cycle, free access to food and
water). Throughout the studies, all efforts were made to
minimize animal pain and suffering. All animal proce-
dures were performed according to the Guide for the Care
and Use of Laboratory Animals of the National Institutes
of Health, as well as the guidelines of the Animal Welfare
Act, and the animal studies were approved by the Insti-
tutional Animal Care and Use Committee of the College
of Medicine, National Taiwan University (certificate no.
20110073).
To evaluate the effects of CAPA on infarct size in
healthy rats, the left anterior descending coronary artery
(LAD) of 8-week-old rats was occluded for 45 min and
reperfused for 2 hours; CAPA and dmCAPA were given
intraperitoneally 30 min before reperfusion, while the
nitric oxide synthase (NOS) inhibitor was given 15 min
before CAPA and dmCAPA administration (Figure 2,
panel 1).
For the induction of diabetes, fasting rats were anes-
thetized with sodium pentobarbital (30 mg/kg) and
intravenously injected with STZ (60 mg/kg freshly dis-
solved in sterile, non-pyrogenic 0.9% NaCl solution in a
volume of 1 mL/kg body weight [35]) through the tail
vein after a 72-h fast [36]. Two weeks after the STZ in-
jection, the animals were considered to have type 1 dia-
betes if the plasma glucose level was > 350 mg/dL and
diabetic features such as polyuria, polydipsia, and hyper-
phagia were observed [37].Figure 2 Ischemia/reperfusion model and chronic treatment time cou
occlusion for 45 min followed by 2 hours of reperfusion. CAPA (3 and 15 m
30 min before reperfusion while the NOS inhibitor (L-NAME; 3 mg/kg, intra
treatment, type 1 diabetes was induced by STZ over 4 weeks in 8-week-old
(panel 2).Four weeks after the STZ induction, the animals were
divided into three groups: age-matched non-diabetic
control animals; STZ-diabetic rats administered vehicle
(distilled water) for 4 weeks; and, STZ-diabetic rats ad-
ministered CAPA (1 mg/kg/day) for 4 weeks (Figure 2,
panel 2).
Surgical procedure of I/R injury in rat heart
Rats underwent myocardial ischemia by the temporary
occlusion of the LAD close to its origin to induce I/R
injury as previously described [38]. Briefly, the rats
were intraperitoneally anesthetized with Inactin® hydrate
(80 mg/kg) and urethane (4 g/kg) [39] on an operating
table equipped with a heater to maintain the proper
temperature. After undergoing a tracheotomy, the animals
were ventilated with room air by a rodent ventilator
(Model 683, Harvard Apparatus, South Natick, MA, USA)
with a stroke volume of 10 mL/kg body weight at a rate of
65 strokes/min. The chest was opened and the ribs were
gently spread. The heart was quickly expressed out of the
thoracic cavity, and a 7/0 silk ligature was placed under
the LAD. The heart was repositioned in the chest and the
animal was allowed to recover for 20 min. A small plastic
snare formed from a polyethylene tubing Portex P-270
cannula was threaded through the ligature and placed in
contact with the heart. The ligature was tightened to oc-
clude the artery and reperfusion was initiated by with-
drawal of the polyethylene tubing. Regional myocardial
ischemia was verified by the presence of a cyanotic zone
in the area of distribution of the occluded vessel and byrse in type 1 diabetic rats. All animals underwent coronary artery
g/kg) and dmCAPA (15 mg/kg) were administered intraperitoneally
peritoneal) was given before LAD occlusion (panel 1). For chronic
rats that were then treated with vehicle or CAPA for 4 weeks
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presence of transmural regional myocardial ischemia
(ST-segment elevation).
Estimation of myocardial damage
At the end of the experiment, the ischemic and perfused
areas of heart were determined by injection of methylene
blue (2 mL; 0.2% in 0.9% NaCl) through the jugular vein
after coronary artery re-occlusion. The rat was sacrificed
and the heart was differentiated into perfused (blue) and
occluded regions. The occluded region (defined as the
"area at risk" [AAR]) was cut out, weighed, and expressed
as a percentage of ventricle weight. Thereafter, the oc-
cluded tissue was sliced into l-mm sections for incubation
in TTC (in saline, 1%) at 37°C for 30 min. The sections
were placed in 10% formaldehyde in saline for 2 days. The
infarcted (white) tissue was excised and weighed. Infarct
size was expressed as a percentage of weight in the oc-
cluded zone [40].
Tissue malondialdehyde (MDA) content analysis
The unperfused zone of cardiac tissue was collected as
described above for the determination of MDA content
using a commercial kit from Sigma-Aldrich Co. LLC
(Catalog Number MAK085). Briefly, tissue samples were
homogenized in phosphate-buffered saline solution and
then completely homogenized by ultra-sonication (40 V
for 15 s). The supernatants were collected in glass tubes
and reacted with sodium acetate solution containing
thiobarbituric acid (TBA) at 95°C for 60 min. After
centrifugation, the supernatants were collected and the
resulting TBA-reactive substances were measured spectro-
photometrically at 532 nm absorbance and expressed as
MDA equivalents (nmol) per milligram of wet tissue as a
measure of lipid peroxidation [41].
Tissue myeloperoxidase (MPO) activity analysis
The occluded zone of cardiac tissue was collected as de-
scribed above for the determination of MPO activity using
a commercial kit from Sigma-Aldrich Co. LLC (Catalog
Number MAK068). Briefly, tissue samples were homoge-
nized in hexadecyl trimethyl ammonium bromide and dis-
solved in potassium phosphate. After centrifugation, the
supernatants were collected and mixed with o-dianisidine
hydrochloride and hydrogen peroxide in phosphate buffer.
MPO activity was measured spectrophotometrically at
412 nm absorbance. MPO activity was defined as the
quantity of enzyme degrading 1 mmol of peroxide per
min at 37°C and was expressed in units per milligram of
wet tissue as a measure of neutrophil activation [40].
Physiological hemodynamic parameters recording
Polyethylene catheters (PE 50) were inserted into the
common carotid artery of the rats to measure bloodpressure and the three-lead electrodes were inserted
subcutaneously to monitor the electrocardiography. The
arterial blood pressure and electrocardiography data
were continuously recorded by a PowerLab 4/30 data
acquisition system (ADInstruments, Castle Hill, NSW,
Australia), while the cardiac function was assessed by a
pressure and volume microtip catheter (1.9 F; Scisense
Instruments, Ontario, Canada). This catheter was inserted
into the left ventricle to measure pressure and volume.
The pressure was measured at a sampling rate of 1,000/s
using a PONEMAH real-time acquisition interface P3P
Plus coupled to an analog-to-digital converter (ACQ-16).
All pressure volume (PV) loop data were analyzed using
the PONEMAH Life Sciences Suite cardiac PV analysis
program from Data Sciences International (St. Paul, MN,
USA). The hemodynamic parameters included left ven-
tricle end-systolic pressure (LVESP), LV end-diastolic
pressure (LVEDP), stroke volume (SV), maximum positive
value (+dP/dt), maximum negative value (−dP/dt) of
the first derivative of the pressure, stroke work (SW),
and ejection fraction. The preload-independent cardiac
contractility parameters were also determined under
conditions of changing preload, elicited by transient
compression of the abdominal inferior vena cava. These
measurements include end-systolic pressure volume rela-
tionship (ESPVR), end-diastolic pressure volume relation-
ship (EDPVR), and the preload recruitable stroke work
(PRSW). In addition, arterial volume elastance (Ea) was
calculated as the ratio of LVEDP at the point in the cycle
where the PV ratio peaks versus the stroke volume under
different experimental conditions [42].
Data analysis
Values are expressed as mean ± standard error of mean
(SEM). The data were subjected to one-way analysis of
variance followed by a multiple-comparison test (Bonferroni-
test). Values of P < 0.05 were considered statistically
significant.
Results
CAPA protected the heart from I/R injury via a nitric oxide
(NO)-dependent pathway
To investigate the cardioprotective effects of CAPA against
I/R injury in vivo, rats were intraperitoneally treated with
CAPA (3 and 15 mg/kg) or dmCAPA (CAPA derivative,
methylation at the hydroxyl groups, no antioxidant activity;
15 mg/kg; Figure 1) 30 min before the reperfusion. Regional
myocardial I/R was established by ligating the LAD of the
rat heart for 45 minutes followed by reperfusion for
2 hours in vivo (Figure 2, panel 1). Hearts were analyzed
by TTC to quantify the infarct size in the AAR. The AAR
did not differ significantly among any of the groups of
hearts (Figure 3A). The administration of 3 mg/kg and
15 mg/kg CAPA dose-dependently reduced I/R-induced
Figure 3 Effects of CAPA, dmCAPA and L-NAME pretreatment on I/R injury. (A) Area at risk (AAR; % of ventricle) and (B) infarct size
(% of AAR) in control rats treated with vehicle and in rats treated with CAPA (3 or 15 mg/kg) and dmCAPA (15 mg/kg). **P < 0.01 and
***P < 0.001 compared to vehicle. (C) AAR (% of ventricle) and (D) infarct size (% of AAR) in control rats treated with vehicle and in rats
pretreated with L-NAME (3 mg/kg) and treated with CAPA (15 mg/kg). ###P < 0.001 compared to vehicle. Data (mean ± SEM) were
obtained from 6–8 animals.
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and 62.9% (P < 0.001), respectively. However, dmCAPA
had no effect on infarct size (Figure 3B).
On the other hand, pretreatment with the NOS in-
hibitor (L-NAME 3 mg/kg) could effectively abolish
the effect of CAPA on infarct size without changing
AAR (Figures 3C and D).Figure 4 Effects of CAPA treatment on MDA levels and MPO activity.
n = 5) after 45 minutes of LAD ligation followed by 2 hours of reperfusion.
of MDA levels (A) and MPO activity (B). *P < 0.05 compared with controls.CAPA decreased the MDA content and MPO activity in I/R
injury
We evaluated the effects of CAPA on lipid peroxidation
and neutrophil activation by evaluating MDA content
and MPO activity, respectively. CAPA administration
(15 mg/kg) significantly reduced MDA content com-
pared to vehicle (P < 0.05; Figure 4A), which means thatWe administered CAPA (15 mg/kg, n = 10) and dmCAPA (15 mg/kg,
After I/R, the tissue in the area at risk was collected for measurement
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during I/R. Moreover, CAPA could reduce MPO activity
compared to vehicle (P < 0.05; Figure 4B). However, nei-
ther MDA content nor MPO activity significantly re-
duced with the same dosage of dmCAPA.The chronic effect of CAPA on body weight and heart
weight in diabetic rats
To investigate the effects of chronic CAPA treatment on
cardiac function in diabetic rats, the STZ-induced type 1
diabetic rats were divided into two groups: one group
treated with vehicle (distilled water) and a second group
treated with CAPA (1 mg/kg, orally). After 4 weeks, both
body weight and heart weight of vehicle-treated diabetic
animals were lower than those of the age-matched ani-
mals (244.2 ± 12.8 g and 0.83 ± 0.03 g vs. 468.5 ± 6.1 g
and 1.27 ± 0.02 g, P < 0.001; Figures 5A and B). CAPA
treatment did not affect body weight or heart weight of
diabetic animals (265.7 ± 19.7 g and 0.93 ± 0.06 g, re-
spectively). However, the ratio of heart weight to body
weight was higher in both diabetic groups treated with
vehicle and CAPA (0.34 ± 0.03 and 0.35 ± 0.02, respect-
ively) than in the control group (0.27 ± 0.01, P < 0.001;
Figure 5C).Figure 5 Effects of CAPA treatment on body weight and heart weigh
weight ratio (C) were calculated. For chronic treatments, the animals were
n = 16; STZ-vehicle, age- and sex-matched diabetic animals administered d
n = 13; and STZ-CAPA, CAPA 1 mg/kg administered orally once daily for 4 w
mean ± SEM. ***P < 0.001 compared with control group.CAPA increased heart rate and mean blood pressure
during the I/R period in diabetic rats
The mean heart rates of STZ-vehicle diabetic rats at the
time before (BS 0), 45 min after ischemia (IS 45), and
60 min after reperfusion (RP 60) were significantly lower
than those of age-matched control (290.9 ± 11.2 bpm,
253.2 ± 11.9 bpm, and 233.0 ± 11.3 bpm vs. 367.9 ±
16.3 bpm, 316.1 ± 16.2 bpm, and 308.2 ± 23.3 bpm, re-
spectively; Figure 6A). CAPA treatment reversed the de-
crease in heart rate in diabetic rats, especially at the
time point of IS 45 compared to the STZ-vehicle group
(302.5 ± 9.1 bpm, P < 0.05). Similarly, the mean blood
pressure was lower in STZ-vehicle diabetic rats than in
control rats 60 min after reperfusion (52.3 ± 3.1 mmHg
vs. 64.6 ± 4.7 mmHg), but CAPA could significantly
ameliorate this effect (65.0 ± 4.2 mmHg, P < 0.05;
Figure 6B).CAPA decreased the infarct size after I/R in diabetic rats
Eight weeks after the STZ induction, the area at risk was
similar among control, STZ-vehicle and STZ-CAPA dia-
betic rats (Figure 7A), while the infarct size was signifi-
cantly increased in the STZ-vehicle diabetic animals
(58.3 ± 2.3% vs. 45.1 ± 4.3% in age-matched normal rats,t. After I/R, the body weight (A), heart weight (B), and heart/body
divided into three groups: control, age- and sex-matched normal rats,
istilled water orally for 4 weeks starting 4 weeks after STZ induction,
eeks starting 4 weeks after STZ induction, n = 6. Data are expressed as
Figure 6 Effects of CAPA treatment on heart rate and mean blood pressure in diabetic rats. The heart rate (A) and mean blood pressure
(B) during the I/R period in control and diabetic rats were recorded. For chronic treatments, the animals were divided into three groups: control,
age- and sex-matched normal rats, n = 16; STZ-vehicle, age- and sex-matched diabetic animals administered distilled water orally for 4 weeks
starting 4 weeks after STZ induction, n = 13; and STZ-CAPA, CAPA 1 mg/kg administered orally once daily for 4 weeks starting 4 weeks after STZ
induction, n = 6. BS 0, basal value just before ischemia; IS 45, 45 min after ischemia but just before reperfusion; RP 60, 60 min after reperfusion; RP
120, 120 min after reperfusion. Data are expressed as mean ± SEM. *P < 0.05 compared with control group and #P < 0.05 compared with
STZ-vehicle group.
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the infarct size to 30.1 ± 8.7% (#P < 0.05; Figure 7B).
CAPA ameliorated I/R-induced cardiac dysfunction in
diabetic rats on PV loop analysis
The cardiac functions of control, STZ-vehicle, and STZ-
CAPA diabetic rats were measured by pressure-volume
loops before and after I/R. The PV loops are derived from
LV pressure versus LV volume in the cardiac cycle dia-
gram by transiently compressing the abdominal inferior
vena cava (Figure 8).
The maximum velocity of both contraction and relax-
ation in STZ-vehicle diabetic rats were significantly
lower than those of age-matched control rats before I/R
(6895.5 ± 393.9 mmHg/s and 5485.0 ± 276.6 mmHg/s vs.
9120.2 ± 634.5 mmHg/s and 7195.4 ± 450.1 mmHg/s,
P < 0.05; Figures 9A and B). CAPA treatment did notFigure 7 Effects of CAPA treatment on infarct size in diabetic rats. Aft
diabetic rats were calculated. For chronic treatments, the animals were divi
n = 16; STZ-vehicle, age- and sex-matched diabetic animals administered d
n = 13; and STZ-CAPA, CAPA 1 mg/kg administered orally once daily for 4 w
mean ± SEM. *P < 0.05 compared with control group and #P < 0.05 compar
45 min after ischemia but just before reperfusion; RP 60, 60 min after reperreverse the decrease in the maximum rate of relaxation
but seemed to have the activity to reverse the decrease
in the maximum rate of contraction in STZ-diabetic
rats. However, there were no significant differences
among any of the groups after I/R.
In LVESP, there were no differences among any of the
groups before or after I/R (Figure 9C), but the mean
LVEDP values of the diabetic groups were higher than
that of the control group at baseline (12.7 ± 1.4 and
12.8 ± 2.1 mmHg in the STZ-vehicle and STZ-CAPA
groups compared to 7.5 ± 0.7 mmHg in the control
group, P < 0.05; Figure 9D).
Figure 9E shows that the ejection fraction significantly
decreased in STZ-vehicle diabetic rats before and after
I/R compared to the control group (48.0 ± 3.0% and
51.0 ± 8.4% vs. 70.6 ± 3.4% and 69.8 ± 12.0%, respect-
ively). CAPA treatment reversed the decrease before I/Rer I/R injury, area at risk (A) and infarct size/area at risk ratio (B) in
ded into three groups: control, age- and sex-matched normal rats,
istilled water orally for 4 weeks starting 4 weeks after STZ induction,
eeks starting 4 weeks after STZ induction, n = 6. Data are expressed as
ed with STZ-vehicle group. BS 0, basal value just before ischemia; IS 45,
fusion; RP 120, 120 min after reperfusion.
Figure 8 Representative pressure–volume loops during preload reduction before and after I/R in diabetic rats. The PV loops are derived
from left ventricalar pressure (LVP) versus left ventricular volume (LVV) in the cardiac cycle diagram by transiently compressing the abdominal
inferior vena cava before and after I/R. A-C, baseline PV loops before I/R; D-F, PV loops after I/R. Control (A, n = 16; and D, n = 6); diabetic rats
administered vehicle (STZ-vehicle; B, n = 13; E, n = 6), diabetic rats administered CAPA (STZ-CAPA; C, n = 6; F, n = 5).
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(42.8 ± 7.2%). There were no significant changes in stroke
volume or stroke work among any of the groups before or
after I/R except that STZ-CAPA diabetic rats had a higher
mean stroke work value than the STZ-vehicle diabetic
group (17785.4 ± 1206.4 vs. 12498.6 ± 902.3 mmHg × μL,
P < 0.05; Figures 9F and G).
In addition to the above parameters, PV loops at differ-
ent preloads could be used to derive several preload-
independent parameters. At baseline, ESPVR, EDPVR, and
PRSW were lower in the STZ-vehicle group than in the con-
trol group (0.40 ± 0.04 mmHg/μL, 0.0037± 0.0012 mmHg/μL,
and 47.8 ± 5.3 mmHg vs. 1.14 ± 0.40 mmHg/μL, 0.0097±
0.0012 mmHg/μL, and 85.5 ± 5.3 mmHg, respectively;
Figures 9I, J, and K), but only ESPVR and PRSW were
significantly reversed in the STZ-CAPA group (1.17 ±
0.30 mmHg/μL and 82.2 ± 6.5 mmHg).
Discussion
The antioxidant effect of CAPA on I/R injury
Myocardial infarction usually results from thrombus [43],
vasospasm [44], routine coronary angioplasty [45], oropen-heart operation [46]. Although restoration of blood
flow is the only way to save the myocardium from ische-
mic injury, reperfusion can exacerbate the myocardial
damage caused by ischemia. The mostly recognized cause
of reperfusion injury is a burst of free radicals including
hydrogen peroxide, hydroxyl radical, and superoxide rad-
ical that is formed during reperfusion and plays an im-
portant role in the pathophysiological mechanism of I/R
injury [4]. Moreover, treatment with antioxidant remedies
or agents capable of inducing antioxidant enzymes such as
glutathione peroxidase and superoxide dismutase have a
cardioprotective effect against I/R injury in experimental
animals in vivo and in vitro [47]. Therefore, antioxidant
therapy may be an effective process for treating myocar-
dial infarction. However, predicting when myocardial in-
farction occurs and preventing the infarction with long-
term antioxidants use is impractical, and administering
medications after ischemia and before reperfusion is a
more reasonable way to treat patients with myocardial in-
farction. Therefore, we administered CAPA 30 min prior
to reperfusion to evaluate the cardiac effect of CAPA in I/R.
The 2,2-diphenyl-1-picrylhydrazyl radical scavenging activity
Figure 9 (See legend on next page.)
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Figure 9 PV loop analysis before and after I/R in diabetic rats. The parameters of PV loop analysis are derived from LV pressure and LV
volume. Ventricular contractility assessment is shown in maximum rising (+dP/dt, A) and falling (−dP/dt, B) velocity, left ventricular end systolic
(LVESP, C) and end diastolic pressure (LVEDP, D) of the ventricular pressure that occurs during the cardiac cycle. E, ejection fraction (%). F,
stroke volume. G, stroke work. Arterial elastance (Ea, H). End-systolic pressure volume relationship (ESPVR, I) and end-diastolic pressure volume
relationship (EDPVR, J). Preload recruitable stroke work (PRSW, K). All values are represented as mean ± SEM before (baseline) and after I/R (I/R).
*P < 0.05 compared to age- and sex-matched non-diabetic control rats. #P < 0.05 versus age- and sex-matched diabetic rats treated with vehicle.
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able to the EC50 of 15.6 ± 2.0 μM CAPE, data not shown),
was in accordance with that seen in other studies of the
structure action relationship of CAPE and CAPA [26,48]
and may reduce tissue oxidative stress and increase tissue
availability of NO. In addition, our studies in type 2 dia-
betic mice have shown that CAPA treatment could in-
crease manganese superoxide dismutase in fat tissue [33],
but whether this effect is involved in improving the
hemodynamic function of STZ-induced diabetic rats re-
mains unknown.
CAPE administration protected the heart from I/R in-
jury with reduced levels of oxidative stress such as MDA
[21]. In our study, CAPA administration reduced MDA
to a level comparable to that seen in the control group.
An analog of CAPA, dmCAPA, which has no radical-
scavenging activity, exhibited no cardioprotective effect
on infarct size, suggesting that CAPA, like CAPE, exerts
a cardioprotective effect mainly through its antioxidant
property. Compared with vehicle treatment, the MPO
activity reduced with CAPA administration, but not with
dmCAPA. This finding suggests that the cardioprotec-
tive effect of CAPA could be partly attributed to the re-
duced inflammatory response by its antioxidant ability.
NO preservation effect of CAPA on I/R injury
Although the role of NO remains controversial, myocar-
dial I/R injury is exacerbated in the absence of endothelial
cell NOS [49]; and endothelial NOS is able to regulate
vascular tension [50], inhibit platelet aggregation [51],
scavenge ROS, and stimulate endothelial regeneration to
protect the heart and blood vessels [52]. CAPA inhibited
lipopolysaccharide/interferon-γ (LPS/IFN-γ)-induced in-
ducible NOS (iNOS) expression and NO production [53],
while a CAPA-induced increase in coronary blood flow
was prevented by a NOS inhibitor, which suggests that
CAPA may enhance coronary blood flow by increasing
NO availability or level [31]. In our study, pretreatment
with the NOS inhibitor L-NAME eliminated the cardio-
protective effect of CAPA on infarct size reduction, sug-
gesting that NO is an important factor responsible for
cardioprotection. We propose that the cardioprotective ef-
fect of CAPA resulted from its own antioxidant property,
which preserves the bioavailable NO in the heart. How-
ever, this assumption requires further supported by more
direct evidence.Effect of chronic CAPA treatment on cardiac dysfunction
in diabetes
Animals with STZ-induced diabetes showed reduced
resting heart rate and pulse pressure [54]. In our study,
the heart rate of diabetic rats was significantly lower
than that of control rats during the I/R period, while
CAPA treatment reversed the reduction after 45 min of is-
chemia (Figure 6A). The mean blood pressures of the
CAPA-treated groups were higher than those of the other
two groups when the hearts were subjected to ischemia
for 45 min and higher than those of the STZ-diabetic ani-
mals after 60 min of reperfusion (Figure 6B). The pressure
preservation effect was in accordance with that seen in
our earlier study concluding that CAPA may preserve the
vasomotor activity in diabetic animals [31]. The mainten-
ance of blood pressure and heart rate by chronic CAPA
treatment may contribute to its protective effect against I/R
injury in diabetic animals.
The STZ-induced diabetic animals underwent
hemodynamic changes in cardiac function measured
by PV loops [55-57]. In our study, the dP/dt max, dP/
dt min, ejection fraction, ESPVR, EDPVR, and PRSW
values were decreased and the LVEDP value was increased
in the STZ-vehicle group; in agreement with the well-
established model of STZ-induced diabetic cardiomyop-
athy. Compared with the STZ-vehicle group, CAPA treat-
ment preserved the basal cardiac function in terms of
PRSW, ESPVR, and ejection fraction, but slight preserva-
tion of PRSW and stroke work occurred after I/R injury.
CAPA treatment did not reverse any parameters of
hemodynamic function after reperfusion; however, the
ameliorations of these parameters at baseline may con-
tribute to the reduction of infarct size after I/R.
The underlying mechanisms of CAPA against cardiac
dysfunction in diabetes
There are several mechanisms involved in the develop-
ment of diabetic cardiomyopathy, including increased
oxidative stress, and activation of the renin-angiotensin
system [58].
In the STZ-induced diabetic rats subjected to I/R in-
jury, hyperglycemia, an independent risk factor, worsens
cardiac performance, cell survival, and tissue injury fol-
lowing myocardial I/R via increased oxidant production
and reduced antioxidant defenses [2,3,59]. In our study,
CAPA ameliorated the I/R injury, but this protective
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were substituted with methoxyl groups, and the antioxidant
activity of CAPA may contribute to the protective effect
on the I/R injury and cardiac dysfunction in diabetes.
Intracellular angiotensin II was proven to have a signifi-
cant role in the pathological process in AT1a receptor-
deficient diabetic mice. The inhibition of intracellular
angiotensin II level by a renin or angiotensin-converting-
enzyme inhibitor prevented the development of cardiac
dysfunction in these diabetic mice [60]. AT-1 receptor an-
tagonists attenuate cardiac failure by decreasing cardiac
inflammation and normalizing matrix metalloproteinase
activity, leading to the alleviation of cardiac fibrosis in
STZ-induced diabetic cardiomyopathy [56]. The inhibition
of Rho-kinase protects the cerebral barrier from ischemia-
evoked injury by modulating endothelial cell oxidative
stress and tight junctions [61] and protects the structure
and function of cardiac mitochondria from diabetes by
attenuating oxidative stress [62]. Acute Rho-kinase in-
hibition improves coronary dysfunction in vivo in the
early diabetic microcirculation [63], while long-term
Rho-kinase inhibition ameliorates myocardial hyper-
trophy, apoptosis, fibrosis, and subsequent cardiac re-
modeling in diabetes [64]. The Rho-associated protein
kinase-mediated signaling pathway is known to be in-
volved in the vascular effects of angiotensin II [65], and
renin-angiotensin system blockade is beneficial to the
cardiovascular system and a known treatment for diabetic
cardiomyopathy [66]. In our earlier study, we found that
CAPA decreased plasma angiotensin II level in mice with
abdominal aortic banding-induced ventricular hyper-
trophy [34], implicating that the angiotensin II-lowering
activity of CAPA may protect the cardiovascular function
in diabetes. The level of iNOS is associated with the in-
duction of RhoA expression in the hearts of diabetic rats
[67], while CAPA inhibits LPS/IFN-γ-induced iNOS ex-
pression [53], implicating that the inhibition of iNOS ex-
pression may contribute to its protection against diabetic
cardiomyopathy.
Recent evidence shows that an increased infarct size is
associated with low levels of myocardial heme oxygenase-
1 (HO-1) during I/R in diabetic rats [2,3]. The nuclear fac-
tor erythroid 2-related factor 2 (Nrf2) signaling pathway
regulates the oxidative stress response, and altered Nrf2
responses may contribute to the observed selective cyto-
toxicity of electrophilic compounds [68]. Nrf2 is a tran-
scription factor that regulates the expression of many
detoxification or antioxidant enzymes [69]. CAPE stimu-
lates ho-1 gene activity by promoting inactivation of the
Nrf2–Keap1 complex, leading to increased Nrf2 binding
to the resident ho-1 AREs, and the induction of HO-1
by CAPE requires Nrf2/ARE pathway activation [70]. In
HO-1 activation, CAPA was as effective as CAPE at indu-
cing HO-1 mRNA (nine-fold over vehicle control) asdetermined by reverse transcription–polymerase chain re-
action [71], and CAPA can induce HO-1 mRNA expres-
sion in rat primary cultured microglia [53]. These data
indicate that CAPA treatment may mitigate infarction in
diabetic rats by inducing HO-1 activity.
Conclusions
STZ-induced diabetic animals suffer from deteriorated
cardiac function with increased myocardial infarction
following I/R. CAPA can reduce the infarct size after I/R
injury, and this study demonstrated that long-term
CAPA treatment reversed cardiac dysfunction in diabetic
animals. The cardioprotective effect of CAPA may result
from its antioxidant activity and the associated preserva-
tion of NO-dependent mechanisms. However, the mech-
anisms of cardiac function preservation in STZ-induced
diabetic rats by 4-week CAPA treatment remain to be
investigated.
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